TO THE EDITOR:
We read Smith and Roberts's analysis of sildenafil with interest (1) . Medical necessity is a complex issue. The authors framed their study as a clarification of the mechanics of insurer decision making yet provide no evidence that insurers do, in fact, make coverage decisions on the basis of cost-effectiveness thresholds. Cost-effectiveness is seldom used as an explicit criterion in such decisions (2) . Thus, the results of this analysis provide little insight into the extent that coverage decisions about sildenafil have been based on cost-effectiveness.
Even if insurers did use a cost-effectiveness criterion, the authors' analysis probably overstated the disutility of erectile dysfunction. None of the cited references directly measured the absolute decrement in utility from erectile dysfunction (3, 4) . Sildenafil is not a cure and probably does not restore all lost utility. Furthermore, utility assessment methods such as the time-tradeoff technique frequently overestimate the gain from improvements in symptoms that are time-limited and sporadic; this occurs in part because patients must determine an equivalent value in terms of lost years of life, which is difficult to do. An alternative method for evaluating sildenafil would be a classic cost-benefit analysis in which patients with erectile dysfunction are asked their willingness to pay for a treatment such as sildenafil (5) . Directing patients to weigh simultaneously the cost and the value of increased health utility for an immediate, timelimited health benefit avoids the aforementioned pitfalls of the costutility method. Such a study could also assess the decreasing marginal value of additional tablets (for example, patients are probably less willing to pay for six versus five tablets per month than for one versus none). Many patients make such decisions when they pay for sildenafil out-of-pocket. A "willingness to pay" study design would be conceptually easier for patients and would more accurately assess their preferences, yielding a more precise estimate of cost-effectiveness.
The article by Smith and Roberts (1) clearly demonstrates the cost-effectiveness of sildenafil for the treatment of erectile dysfunction. We applaud them for conducting such high-quality research.
However, we are concerned about the statement implying that sildenafil causes "severe adverse effects . . . sudden death, myocardial infarction, and arrhythmia, among others." This statement appears to be based on a misinterpretation of reports of spontaneous adverse events (such as the U.S. Food and Drug Administration's MedWatch system).
The sildenafil clinical trial database now includes 36 doubleblind, placebo-controlled studies and 46 open-label studies, with more than 11 000 person-years of observation for sildenafil and over 700 person-years for placebo. The incidence of serious adverse events, such as myocardial infarction and death, in these trials has remained consistently low; no differences have been noted between men randomly assigned to sildenafil and those assigned to placebo, even among patients with known cardiovascular conditions or risk factors (2) . Prospective studies (3) and retrospective database reviews (4) have shown no difference in serious cardiovascular adverse events between sildenafil and placebo recipients and have reported no deleterious effects on key cardiac measures, including coronary artery blood flow (5) and rate-pressure product.
Cardiovascular disease and erectile dysfunction share risk factors, and most men with erectile dysfunction have one or more of these risk factors. More than 10 million men have filled prescriptions for sildenafil, and some cardiovascular events are likely to occur by chance alone. The number of spontaneous reports received is not high compared to the background rate of events in these men, most of whom are between 50 and 70 years of age.
We feel that the comment in the article suggesting a causal relationship between sildenafil and serious cardiovascular events is incorrect and that an extensive body of evidence (hemodynamic studies, clinical trials, and postmarketing experience) demonstrate the excellent safety profile of the drug when it is prescribed in accordance with the product label. Measuring quality of life is difficult, but this difficulty does not imply that meaningful, individual differences in preferences for health states do not exist, nor does it "prove wrong the assumption of cost-effectiveness analysts." Instead, it shows that policy informed by cost-effectiveness analyses must account for a wide range of utilities and the uncertainties in their measurement. As we show in our article, sildenafil is reasonably cost-effective compared to accepted medical interventions when disutility from erectile dysfunction is varied widely through the values obtained from published studies. The utility of erectile dysfunction for wives alone in Volk and colleagues' article (1) is tempered in the same article by the value given by husbands and wives jointly, 0.84. We won't speculate on whether Adam Smith would value erectile function as diamonds or as water.
Groeneveld and Duncan advocate using willingness-to-pay and cost-benefit techniques to explore sildenafil coverage decisions, citing weaknesses in utility assessment done by using time-tradeoff techniques. We argue that erectile dysfunction and other transient and recurrent illnesses impart significant chronic disutilities that allow reasonable use of time-tradeoff assessment. In addition, many health care professionals are uncomfortable with placing an explicit value on human life, as is required in cost-benefit analysis, and with the tendency of analyses using willingness-to-pay techniques to favor wealthier populations (2) . Cost-effectiveness analyses do not seek to place an absolute value on health or life. Instead they compare interventions, their costs, and their resulting quality of life. We agree that insurers use many criteria other than cost to make coverage decisions. However, it is unclear whether insurers would consider cost-benefit analyses differently than they do cost-effectiveness analyses. Outside of the United States, cost-effectiveness analyses are often used to inform pharmaceutical coverage decisions (3) .
Use of decision analytic techniques allows examination of worstcase scenarios for various measures to understand their impact on results (4). As stated in our paper, the values for morbidity and mortality related to sildenafil therapy used in the analysis are much higher than have been reported, illustrating that even unrealistically high values have little impact on the cost-effectiveness calculation.
The Informationist

TO THE EDITOR:
The recent editorial by Davidoff and Florance (1) raised many important issues about medical information. I beg to differ, however, with their conclusion that a new health profession, the "informationist," is the "obvious answer" to the problem of information retrieval. We already have, as part of the health care team, pharmacists who specialize in the provision of just such information. In fact, pharmacists are uniquely qualified as drug and medical information specialists, thanks in part to the ever-expanding clinical curricula at pharmacy programs throughout the United States. Combined with training in retrieval and evaluation of biomedical literature, this clinical expertise enables pharmacists to remain the optimal source of information for health care professionals (2) . Multidisciplinary teams that include pharmacists have consistently documented substantial cost savings and improved patient outcomes (3), a reduced incidence of adverse drug events caused by prescribing errors (4) , and decreased mortality rates in the hospital and managed care settings (2, 5) .
It is time to move into the new millennium with a definition of "health care team" that includes and acknowledges pharmacists as the well-trained and highly skilled professionals that they have proven themselves to be. In answer to Davidoff and Florance's question, "If practicing clinicians don't retrieve information from the literature themselves, who will?"-Drug information pharmacists already are! Deborah B. Root Jorgensen, PharmD Candidate Virginia Commonwealth University/MCV School of Pharmacy Richmond, VA 23298-0581 TO THE EDITOR: I agree with Davidoff and Florance (1) that the medical profession can and should do more to link the literature to the point of care, but I am not as pessimistic as the authors about physician capabilities in this regard. Twenty years ago, a computer literature search at a major medical school library required the help of a librarian and approximately 48 hours before a printout of potentially useful abstract titles appeared. Access to selected articles would take another day or two. Today, in a busy clinical setting, it is possible to access clinically useful information (which I operationally define as information that confirms or alters the clinical impression or the therapeutic choice) in about 85% of attempts, with a mean time expended of 8 minutes. While this time and effort may still be just outside the realm of universal applicability, continued effort and better electronic linking of clinical encounters to the literature are likely to shorten the time even more. Physician skill in assessing the utility of literature is unlikely to improve if we assign this key task to others.
Stephen Sandroni, MD St. Mary's Hospital Waterbury, CT 06706 TO THE EDITOR: The editorial by Davidoff and Florance poses an important question to internists (1) . Is it time to add another specialist to the clinical care team to address our failure to apply evidence-based clinical practice (EBCP)? Physicians certainly use a wide variety of sources of information, some much more credible than others. The accessibility and applicability of the source are important; some studies have suggested that "organic" resources, such as colleagues, offer additional advantages to physicians over and above their technical attributes (2) . Therefore, it is not surprising that clinical medical librarians can be an important information resource.
Nonetheless, the "informationist" may not be the best solution to our failures to use EBCP. The formulation of the clinical question and application of evidence to specific patient problems are key elements of EBCP (3). Physicians must still master these skills so that they can effectively apply information from health information resources and clinical librarians to patient care (4). The interconnectivity of the Internet, the improved search capabilities of PubMed, the online Cochrane Library, and various other Internet EBCP resources hold great promise. Even more exciting is the potential for "point of care" evidence-based practice. Already, hand-held computers can provide immediate access to a variety of current, clinically applicable medical knowledge resources (5) . Recent advances in hand-held clinical computing combined with online evidence-based resources and wireless Internet access will soon place in our grasp the resources necessary for real-time EBCP.
Physicians have thus far failed our obligation to base our decisions on the best available information. Davidoff and Florance have appropriately issued a challenge to internists. We must better prepare students, residents, and ourselves to access and apply the available medical evidence. We must also work closely with medical librarians and information system colleagues to develop the tools to incorporate high-quality evidence at the bedside. Only by these means can all seriously ill patients benefit from evidence-based practice delivered by that most cost-effective of "informationists," the internal medicine physician.
Bruce Houghton, MD Eugene C. Rich, MD
Creighton University Omaha, NE 68131 TO THE EDITOR: I commend Davidoff and Florance for their editorial on the future of medical literature access (1). I was a "clinical librarian" for 12 years at a Connecticut hospital, following in the footsteps of such greats as Gertrude Lamb (2). As subsequent studies have shown, rapid delivery of medical information by a trained clinical librarian regularly interacting with physicians has immense practical value to the patient (3-5).
Two points covered in Davidoff and Florance's editorial need to be expanded upon: It is a dirty little secret that hospital libraries are dying. Managed care, health maintenance organizations, cuts in government funding for residency programs, and other trends are destroying support services in hospitals. Medical libraries that made impressive gains in the 1970s and 1980s are fighting for their lives. With the onset of the digital age, information is no longer contained in books. It is contained in the people who are skilled at accessing it. With a laptop computer, a trained librarian can be anywhere in the world and still access great storehouses of information with a few clicks of a mouse. Librarians should not be solely in libraries, which are rapidly becoming temples to static or dead data, but also in boardrooms, on research teams, and at morning report.
In this fast-changing world, the ability to access and retrieve information is a vital survival skill, whether you are running a Fortune 500 corporation or treating a patient with a condition you have never seen before. Thank you again for giving the informationist a much-needed breath of life.
Michael J. Schott, MS, MLS
West Virginia University Charleston, WV 25304 IN RESPONSE: Ms. Root Jorgensen cites evidence, as did the authors of several other letters, that drug information specialists can contribute to improvements in patient outcomes, reduce prescribing errors, save money, and even decrease mortality. Clinicians look for information on drug prescribing more often than information of any other type (1-3) , so the observation that drug information specialists have a substantial impact on clinical care is predictable. Predictability aside, we take the success of drug information specialist programs as important, albeit indirect, support for the potential value of informationists throughout clinical medicine, since the training and clinical role of drug information specialists are similar to those we propose for informationists. Drug information specialists can clearly serve as a model for information subspecialists within a more general informationist framework; whether they can effectively assume a broader informationist role remains to be seen.
Dr. Sandroni's demonstration of successful searches in a mean time of 8 minutes is encouraging. Others (4) have found, however, that even expert searchers need an average of nearly 30 minutes per search. Moreover, judging from the observation that clinicians themselves at best perform less than one electronic literature search per week (2), relying almost exclusively on nonelectronic information sources that require only 0.5 to 1.5 minutes per question to give them an answer (3), even 8 minutes per search may be unacceptably long for busy practitioners.
We agree with Houghton and Rich that hand-held digital assistants, particularly wireless models, may speed up real-time information retrieval in clinical settings. The true potential of these devices has yet to be explored, however, and we suspect that in the long run they will be more useful to informationists than to clinicians themselves.
Finally, while Mr. Schott's elegy on the impending death of hospital libraries is understandable, his pessimism, in our view, is justified only if medical libraries are defined narrowly as archives. Archiving is a crucial function of libraries, but while it is still necessary it is no longer sufficient for the survival of libraries. Medical information is not simply a resource to be stored and treasured but a living, dynamic force. Libraries and librarians therefore need to redefine themselves and their roles accordingly; if they do, they will flourish. In that connection, we have been pleased to learn that our proposal for informationists is already being actively considered in the medical library community as a credible way of dealing with these new realities (5).
Frank Davidoff, MD Editor
Valerie Florance, PhD Association of American Medical Colleges Washington, DC 20037
Serum Homocysteine and Stroke in Atrial Fibrillation
TO THE EDITOR: Atrial fibrillation (AF) increases the risk for stroke (1) . Although warfarin substantially decreases this risk (2), the need for frequent blood sampling to ensure efficacy and to monitor inherent risks of treatment, especially in elderly persons (3) , are serious limitations. Cohort studies of AF have defined clinical subgroups with differing risks for stroke (2) . However, no chemical predictor of stroke in AF has previously been reported. Elevated serum and plasma homocysteine concentrations have been identified as a risk factor for atherothrombotic diseases in general (4) and for stroke in particular (5) . It would therefore be of interest to know the relation of homocysteine levels to stroke in patients with AF.
One hundred consecutive patients with established cardiovascular diseases had homocysteine measurements by fluorescence polarization immunoassay technology (Abbott Laboratories, Chicago, Illinois). The clinical findings, including homocysteine levels, in patients with AF (n ϭ 40) were similar to those in patients who had never had this arrhythmia (n ϭ 60). However, those with AF who had had a stroke (typical clinical presentation with confirmation by radiologic imaging) but had fully recovered (n ϭ 12) had higher homocysteine levels than those with AF who had never had such an event (n ϭ 28) (mean [ϮSD], 16.7 Ϯ 1.5 mol/L vs. 11.9 Ϯ 0.8 mol/L; P Ͻ 0.003). Patients with stroke were also older (79 Ϯ 1 years vs. 70 Ϯ 2 years; P Ͻ 0.001). The occurrence of stroke with AF paralleled the sharp increase in homocysteine level observed at the end of the seventh decade (Figure) . For the entire cohort, homocysteine levels correlated with age (r ϭ 0.56; P Ͻ 0.001) and serum creatinine concentration (r ϭ 0.70; P Ͻ 0.001).
These findings demonstrate that homocysteine levels are higher in patients with AF who have had a stroke than in those who have not. Also, the increased homocysteine levels observed in elderly persons provide a possible explanation for the sharp increase in stroke in patients with AF after 65 years of age (2) . Associations, however, do not prove causality. Only a randomized clinical trial in which a lowered homocysteine level is shown to reduce stroke would establish this relation. 
Celecoxib-Induced Cholestatic Hepatitis
TO THE EDITOR:
A 55-year-old nonalcoholic obese woman who was allergic to sulfa presented with a 5-day history of jaundice, malaise, and pruritic rash that began 3 weeks after she took celecoxib, 200 mg/d, for radiculopathy-associated pain.
The patient's medical history included type 2 diabetes mellitus, hypertension, hyperlipidemia, and chronic lymphocytic leukemia, all of which were stable at presentation. Long-standing medications included indapamide, conjugated estrogens, glyburide, and atorvastatin. The patient had stopped taking celecoxib 5 days before hospitalization.
Physical examination showed jaundice and a diffuse maculopapular, erythematous rash on the upper abdomen, back, and chest. The abdomen was diffusely tender without organomegaly. Laboratory results included an aspartate aminotransferase level of 3.22 kat/L, an alanine aminotransferase level of 4366 nkat/L, an alkaline phosphatase level of 4.73 kat/L, a total bilirubin level of 208.6 mol/L (12.2 mg/dL), a direct bilirubin level of 171.0 mol/L (10.0 mg/ dL), and an albumin level of 3.2 g/L. Peripheral eosinophilia was present. Results of viral hepatitis serologic testing and autoantibody tests were negative. Abdominal ultrasonography showed cholelithiasis. Liver biopsy revealed marked intrahepatocyte cholestasis with eosinophil-rich inflammation involving the portal tracts, consistent with a drug reaction. Eleven weeks after discharge, the patient remained fatigued and aminotransferase and bilirubin levels were mildly elevated. The patient's symptoms and laboratory abnormalities were completely resolved at 4 months.
The temporal relationship between the institution of celecoxib therapy and the development of rash, hepatic eosinophilia, and jaundice implicate celecoxib as the cause of a hypersensitivity-like liver injury. The clinical and biochemical pattern and liver histologic findings are similar to those seen with sulfonamide-induced cholestatic hepatitis (1, 2) .
In our patient, confounding factors may challenge the causal relationship between celecoxib and hepatotoxicity. She was taking other potentially hepatotoxic medications, including indapamide, conjugated estrogens, atorvastatin, and glyburide. However, these medications had been used for several years, and periodic monitoring of liver biochemical test results had shown repeatedly normal levels.
Clinicians may not be aware that celecoxib is a sulfonamide and that the presence of a sulfa allergy may predispose patients to a drug-induced cholestatic hepatitis.
